{"id":"NCT02899962","sponsor":"LEO Pharma","briefTitle":"LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris","officialTitle":"LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-15","primaryCompletion":"2019-06-26","completion":"2019-06-26","firstPosted":"2016-09-14","resultsPosted":"2020-08-20","lastUpdate":"2020-08-20"},"enrollment":722,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis Vulgaris"],"interventions":[{"type":"DRUG","name":"LEO 90100 aerosol foam","otherNames":[]},{"type":"DRUG","name":"LEO 90100 aerosol foam vehicle","otherNames":[]}],"arms":[{"label":"LEO 90100 aerosol foam","type":"ACTIVE_COMPARATOR"},{"label":"LEO 90100 aerosol foam vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"A phase 3 trial comparing the efficacy and safety of LEO 90100 aerosol foam with the aerosol foam vehicle used twice weekly as long-term maintenance therapy in subjects with psoriasis vulgaris.\n\nA 12-month, international, multi-centre, randomised, vehicle controlled, double-blind, 2-arm, parallel group trial.","primaryOutcome":{"measure":"Time to First Relapse","timeFrame":"From Randomisation (Week 4) until first relapse or End of Treatment (Week 56 or early withdrawal)","effectByArm":[{"arm":"LEO 90100 Aerosol Foam","deltaMin":56,"sd":null},{"arm":"LEO 90100 Aerosol Foam Vehicle","deltaMin":30,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":58,"countries":["United States","Canada","France","Germany","Poland","United Kingdom"]},"refs":{"pmids":["35297108","34339017","32965655"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":650},"commonTop":["Nasopharyngitis","Vitamin D deficiency","Upper respiratory tract infection","Rebound psoriasis","Back pain"]}}